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The wide variety of excipients available calls for evaluation of their functionality, in this case 
of the pharmaceutical performance of microcrystalline celluloses and sodium cross-linked 
carboxymethylcelluloses from different sources. This evaluation includes parameters such as powder 
flow, compactibility, ejection pressure and dissolution from fast-release tablets as well as from floating 
granules and controlled-release tablets. In a previous study, the excipient Carmacel® presented better 
disintegration properties compared to Croscarmellose®. However, the evaluation showed better 
compactibility performance for Croscarmellose®. These characteristics were observed using pure 
excipients. Nevertheless, these advantages have not been confirmed in tests employing immediate-release 
or modified-release formulations containing metronidazole. Regarding microcrystalline celluloses, the 
present comparative evaluation between pure Alfacel ® types 101 and 102 and pure Avicel® types 101 and 
102 showed better compactibility performance for the latter. However, for metronidazole formulations, 
this advantage was not evident in the innovative excipient. Notwithstanding, this study revealed better 
compactibility performance of microcrystalline cellulose type 101. In terms of powder flow properties, 
Avicel® and Alfacel® showed similar performance. However, the results revealed better powder flow 
employing microcrystalline cellulose type 102 for both excipients. Based on the results obtained, it 
can be concluded that the employment of innovative and generic excipients have both advantages and 
disadvantages. The observed differences however, tend to disappear as the excipients are diluted in a 
formulation, thereby equalizing their influence on product performance. 
Uniterms: Excipients/functionality. Microcrystalline celluloses. Sodium cross-linked 
carboxymethylcelluloses. Croscarmellose. Carmacel. Avicel. Alfacel. Tablets/disintegrants. 
Pharmaceutical dosage/forms.
A variedade de excipientes disponível no mercado requer adequada seleção desses no que se refere à sua 
funcionalidade, como no caso de celuloses microcristalinas (Avicel® 101 e 102 e Alfacel® 101 e 102) e 
de carboximetilceluloses de sódio reticuladas (Croscarmellose® e Carmacel®), provenientes de diferentes 
fontes. Assim sendo, o desempenho farmacotécnico desses excipientes deve ser avaliado quanto ao 
fluxo e característica de compactação do pó, à pressão de expulsão do núcleo, ao perfil de dissolução de 
comprimidos de liberação imediata e modificada assim como de grânulos flutuantes. Em um trabalho 
anterior, o excipiente Carmacel® apresentou melhores propriedades de desintegração quando comparado 
ao Croscarmellose®, porém, no que se refere à característica de compactação a avaliação revelou melhor 
desempenho para o Croscarmellose®. Tais características foram observadas empregando apenas os 
excipientes. Porém, tais vantagens não foram confirmadas nos ensaios empregando as formulações de 
liberação imediata ou de liberação modificada contendo metronidazol. No que se refere às celuloses 
microcristalinas, a avaliação comparativa entre Alfacel® puro dos tipos 101 e 102 e Avicel® puro dos 
tipos 101 e 102 revelou melhor desempenho desse último quanto à característica de compactação, no 
entanto, para as formulações contendo metronidazol não foi possível demonstrar tal vantagem para o 
excipiente inovador. Porém, o estudo revelou melhor desempenho quanto à característica de compactação 
da celulose microcristalina do tipo 101. Quanto às propriedades relativas ao fluxo de pó, o Avicel® e o 
Alfacel® apresentaram desempenho semelhante. Porém, o estudo revelou melhor fluxo de pó no emprego 
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da celulose microcristalina do tipo 102, para ambos os excipientes. Considerando os resultados obtidos, 
pode-se concluir que o emprego dos excipientes inovador e genérico apresentam vantagens e desvantagens. 
No entanto, as diferenças observadas tendem a desaparecer em função da diluição desses na formulação, 
equalizando, dessa forma, sua influência no desempenho do produto. 
Unitermos: Excipientes/funcionalidade. Celuloses microcristalinas. Carboximetilceluloses de sódio 
reticuladas. Croscarmellose. Carmacel. Avicel. Alfacel. Tabletes/desintegrantes. Dosagem farmacêutica/
formas.
INTRODUCTION
The formulation process require a clearly defined 
product profile along with information on the physical 
and chemical properties of the active ingredient, of the 
most common excipients, and on the operation principles 
of the manufacturing equipment available for commercial 
production. The active pharmaceutical ingredient (API) 
properties of dose, solubility, compactibility etc., are the 
major constraint on formulation, and define how the active 
ingredient will respond to the stresses of the manufacturing 
process and to its ultimate use by the patient. Once the 
API properties are fully understood, the excipients and the 
process pathway can be carefully selected to overcome any 
apparent deficiencies in the API properties. This leverages 
the unique functionality of each excipient and the benefits 
of each manufacturing unit operation (Hancock, 2009).
The characterization of pharmaceutical excipients 
using a materials science approach has helped design drug 
formulations to obtain a desired set of performance proper-
ties. For tablets, a better understanding of the compression 
properties of a drug, alone and in combination with other 
potential components, facilitates the development of better 
formulations and products. The mechanical properties 
of a material play an important role in powder flow and 
compaction properties by influencing particle-particle in-
teraction and cohesion, while reliable mechanical property 
information can be useful in (a) choosing a processing 
method, (b) selecting excipients with properties that will 
mask the poor properties of the drug, and (c) helping to 
document what went wrong. Despite the complexity of 
the mechanics of pharmaceutical systems, mechanical 
property measurements constitute the most systemic, 
rational approach to formulation design (Skinner, 1998).
The excipients are included in the formulation 
because they possess properties that, in conjunction with 
processing, allow the medicine to be manufactured to meet 
the required specification. These desirable excipient pro-
perties relate to its functional performance or functionality. 
Functionality has been defined as: a desirable property of 
an excipient that aids manufacturing and improves the ma-
nufacture, quality or performance of the drug product. The 
reality is that functionality can only be properly assessed 
in the context of the finished pharmaceutical product, and 
each formulation will have its own particular requirements 
for functionality (Moreton, 2009).
Because functionality is linked inextricably to the 
formulation and process, and all formulations are diffe-
rent, establishing a widely accepted standard for a parti-
cular excipient’s functionality proves problematic. One 
formulation’s functionality can be another formulation’s 
dysfunctionality (Moreton, 2004). However, surrogate func-
tionality tests can be considered for use as a general reference.
In a previous study, the surrogate functionality of 
different microcrystalline celluloses and sodium cross-
linked carboxymethyl celluloses was investigated. The 
surrogate functionality properties used were particle 
morphology and particle size distribution, compactibility, 
ejection pressure and the disintegration properties of pure 
excipients and their compressed tablets. The innovative 
celluloses Avicel and Croscarmellose showed advantages 
over the generic celluloses Alfacel and Carmacel. Avicel 
PH 101 and 102 showed an average of 26 % greater com-
pactibility than both types of Alfacel, while the compacti-
bility of Croscarmellose was greater than that of Carmacel 
by about 50%. Avicel tablets compacted at a compaction 
pressure of 47 MPa exhibited shorter disintegration times 
(3.7 min) than Alfacel tablets (28 min), while Carmacel 
showed better disintegrant properties than Croscarmellose. 
This occurred despite similar particle morphology, size 
and size distribution. As expected for hygroscopic and in-
soluble materials, all celluloses showed low ejection pres-
sures and no significant difference could be established 
among the different celluloses (Díaz, Villafuerte, 2010).
Excipients can be categorized by the function per-
formed in a formulation. However, many excipients have 
multiple functions. For example, microcrystalline cellu-
lose can function as a diluent, a binder and a disintegrant. 
Tablet excipients are grouped into different functionalities, 
one approach includes the following five functionalities: 
adsorbents, binders/diluents, disintegrants, glidents, and 
lubricants (McCarty, 2003).
Metronidazole, a 5-nitroimidazole with bactericidal 
activity against most anaerobic and facultative anaerobic 
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bacteria and protozoa, is widely used for the treatment of 
anaerobic bacterial and protozoal infections. The drug has 
few adverse reactions, most commonly nausea, dry mouth, 
vomiting, and diarrhea. Neurologic toxicity is rare and 
has included peripheral neuropathy, headache, dizziness, 
syncope, vertigo, and confusion (Patel et al., 2008).
Metronidazole has been used as a model drug for 
floating tablets with a probable gastric retention, because 
of a general assent about the benefits of eradication of H. 
pylori in patients with peptic ulcer. Drugs administered 
systemically are absorbed into the blood stream and dis-
tributed throughout the host patient via the circulatory 
system, which can result in bacterial resistance. When 
administered locally, this limits the adverse effects of 
systemic administration and there is a higher concentration 
of medication reaching the target site (Lara-Hernández 
et al., 2009). Metronidazole has been used also for local 
eradication of Helicobacter pylori in the form of floating 
beads (Javadzadeh et al., 2009).
Although single unit floating dosage forms have 
been extensively studied, these single unit dosage forms 
have the disadvantage of a release all or nothing emptying 
process, while the multiple unit particulate system pass 
through the GIT to avoid the vagaries of gastric emptying 
and thus release the drug more uniformly. The uniform 
distribution of these multiple unit dosage forms along the 
GIT could result in more reproducible drug absorption and 
reduced risk of local irritation (Tanwar, 2006).
Recently, many studies have reported solid dis-
persions using Gelucires (polyglycolized glycerides) by 
fusion and solvent evaporation techniques. Gelucire-39/01 
is a lipophilic carrier which is frequently used for this 
purpose; the suffixes 39 and 01 refer to its melting point 
and its HLB, respectively. Gelucires belong to a family of 
materials made up of glycerides and fatty acid esters of 
polyethylene glycols. Gelucires are available with a range 
of properties depending on their hydrophilic lipophilic 
balance (HLB). They have a HLB over a range of 1 to 18, 
and a melting point between 33 °C and 70 °C (Shrivastava 
et al., 2009; Patel et al., 2007a).
Gelucires containing only glycerides or a mixture of 
glycerides and PEG esters (Gelucire 54/02, 50/13, 43/01) 
are used in preparations of sustained release formulations. 
Gelucire 43/01 has been used for the design of multi-unit 
floating systems of a highly water-soluble drug, diltiazem 
HCl. The granules were retained in the stomach for at least 
6 hours. Approximately 65% to 80% drug was released 
over 6 hours with initial fast release from the surface 
(Shimpi et al., 2004).
The aim of this study was to assess the functionality 
of Avicel, Alfacel, Croscarmellose and Carmacel P (CC) in 
metronidazole fast-release formulations containing diffe-
rent microcrystalline celluloses and cross-linked sodium 
carboxymethylcelluloses. Additionally, the study sought 
to assess the functionality of the cross-linked sodium 
carboxymethylcelluloses in controlled-release floating for-
mulations containing metronidazole and Gelucire 39/01.
MATERIALS AND METHODS
Materials
The materials used in this study were microcrys-
talline cellulose, Avicel PH 101, batch P107818846 and 
PH 102, batch: P206816698, FMC Biopolymer; mi-
crocrystalline cellulose, Alfacel type PH 101, batch 12, 
and type PH 102, batch 13, Reliance Cellulose Products 
Limited; cross-linked carboxymethylcellulose sodium, 
Croscarmellose sodium, batch T0801C, FMC Biopolymer; 
cross-linked carboxymethylcellulose sodium, Carmacel 
P(CC), batch 02, Reliance Cellulose Products Limited; 
metronidazole, batch: 03121402, Química Alkano; Geluci-
re 39/01, batch: 5E0907-2 Y GE2007-2, Lubrizol; Stearic 
acid, batch: 31503361, Helm de México. 
Metronidazole tablets
Table I shows the formulations employed to obtain 
metronidazole fast-release tablets, using Croscarmellose 
and Carmacel as disintegrants and Avicel PH 101 and 102 
as diluents, as well as Alfacel types 101 and 102.
The materials corresponding to each formula were 
sieved (sieve number 20) prior to being mixed. The drug 
and 30% of the diluent were mixed with a spatula in a mor-
tar for 15 min. After addition of the rest of the diluent plus 
the disintegrant, the powders were mixed for a further 15 
TABLE I - Metronidazole formulations containing different 
microcrystalline celluloses and cross-linked sodium 
carboxymethylcelluloses
Components (%) F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8
Metronidazole 50 50 50 50 50 50 50 50
Alfacel PH 101 ----- ----- 47 47 ----- ----- ----- -----
Alfacel PH 102 ----- ----- ----- ----- ----- ----- 47 47
Avicel PH 101 47 47 ----- ----- ----- ----- ----- -----
Avicel PH 102 ----- ----- ----- ----- 47 47 ----- -----
Stearic acid 1 1 1 1 1 1 1 1
Croscarmellose ----- 2 2 ----- ----- 2 ----- 2
Carmacel P-(CC) 2 ----- ----- 2 2 ----- 2 -----
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min. Finally, the previous mixture was mixed for 15 min 
with the lubricant. The tablets were flat, with a diameter 
of 12.8 mm and a total tablet weight of 500 mg, equivalent 
to a metronidazole content of 250 mg. The powders were 
compacted for 10 seconds in hydraulic presses adapted in 
our laboratory with a manometer measuring up to 50 MPa 
and 105 MPa, accurate to ± 2% and ± 1% respectively, 
and similar to the Carver standard manual presses (Carver 
Inc., 2010).
Metronidazole controlled-release floating 
formulations
Table II shows the formulations used to obtain 
metronidazole/Gelucire controlled-release floating gra-
nules and tablets, using Croscarmellose and Carmacel as 
disintegrants. Floating granules containing metronidazole 
were prepared using the melt granulation technique. The 
drug:lipid ratio used to prepare the different formulations 
was 50:40. To study the effect of the disintegrants Cros-
carmellose and Carmacel at different proportions were 
added separately to the formulations. The proportions of 
disintegrants were 5, 10 and 15 parts. Lipid was melted at 
50°C, and the drug and disintegrants mixture was added, 
mixed well, and cooled to room temperature. The mass 
was passed through a number 20 sieve to obtain uniform-
sized granules.
The tablets were flat with a diameter of 12.8 mm and 
a weight equivalent to 500 mg metronidazole per tablet. 
The powders were compacted for 10 seconds in hydrau-
lic presses adapted in our laboratory with a manometer 
measuring up to 50 MPa and 105 MPa, accurate to ± 2% 
and ± 1% respectively, and similar to the Carver standard 
manual presses (Carver Inc., 2010).
Powder flow
The equipment used for this test was adapted in our 
laboratory and similar to that used to determine the tap 
density of powders (Kibbe, 2000). The tapper was set to 
a rate of 74 taps per minute and adjusted to elevate the 
graduated cylinder up to a height of 18 mm. This device 
uses a 100-mL graduated cylinder joined to a glass funnel 
with an orifice of 20 mm that can be closed with a glass 
rod. Once the sample is weighed and placed in the closed 
funnel, the device is started while removing the glass rod 
at the same time. The time required for the 30 g of powder 
to empty from the funnel through the funnel orifice, is used 
to calculate the speed of the powder flow. The registered 
results were the average of 10 repetitions on the same 
sample without further treatment.
Compactibility and ejection pressure
Corresponding quantities of the powder blends 
were compressed for 10 s at different compaction pres-
sures in a hydraulic press. The tablet crushing strength 
was measured in triplicate, registering the results as an 
average. For this purpose, hydraulic presses adapted in 
our laboratory were used with a manometer measuring 
up to 1.1 MPa and 4.1 MPa, accurate to ± 1 and 2%, res-
pectively, similar to the Carver standard manual presses 
(Carver Inc., 2010) with a pointer for the maximal pres-
sure reached. The procedure entailed placing each tablet 
diametrically between two flat surfaces and applying 
pressure until the tablet broke. The maximal pressure 
reached was taken as the tablet crushing strength. In the 
same way, the necessary pressure to eject the formed 
tablets was taken as the ejection pressure. For this pur-
pose, the pressure was applied on a punch while the die 
was supported on an acrylic cylinder, allowing the tablet 
release from the die where it was formed.
Dissolution of metronidazole
Dissolution studies were performed in 900 ml of 
HCl 0.1N using the paddle method (USP 26), at 50 rpm 
and 37 ºC (JT R09, TEMSA, Mexico). The amount of 
metronidazole released over time was determined by with-
drawing samples at various time intervals. The concen-
tration of metronidazole was obtained by measuring the 
absorbance at 276 nm in a Beckman DU-650 ultraviolet 
spectrophotometer. This procedure was used to evaluate 
all the metronidazole formulations, including immediate-
release tablets, floating granules and controlled-release 
tablets. The results for each time point of three different 
dissolution curves are registered as an average in the 
figures. These average values were used to calculate the 
regression parameters of each dissolution curve represent-
ing a given formula.
TABLE II - Metronidazole formulations containing Gelucire 
39/01 and different proportions of sodium cross-linked 
carboxymethylcellulose
Components (parts) G05 G06 G07 G08 G09 G10
Metronidazole 50 50 50 50 50 50
Gelucire 39/01 40 40 40 40 40 40
Croscarmellose 10 5 15 0 0 0
Carmacel P-(CC) 0 0 0 10 5 15
Functionality of innovative and generic celluloses in metronidazole formulations 45
RESULTS AND DISCUSSION
Powder flow
Flow characteristics of the pharmaceutical excipi-
ents are of major concern with respect to the handling and 
compaction of the powder materials, especially for directly 
compressible excipients. Blend flow is important to ensure 
bulk blend transfer into the tablet press hopper and consis-
tent die fill. Variation or difficulty in the bulk flow or die 
fill can contribute to tablet weight variations.
Figure 1 shows the powder flow through an orifice 
of 20 mm of different metronidazole formulations. As 
can be seen, formulations with microcrystalline cellulose 
type 102 exhibited better powder flow, with an average of 
16.7 g/s, followed by formulations with microcrystalline 
cellulose type 101 with an average of 9.2 g/s. This is attri-
buted to the greater average particle size of the type 102 
formulation. Avicel PH 102 showed better fluidity because 
of its more granular form and larger particle size (Ahjel, 
Lupuliasa, 2008). Although the average powder flow of 
the raw materials Alfacel (23.8 g/s) and Avicel (29.1 g/s) 
differs by about 20%, the differences between formula-
tions containing Alfacel and Avicel are smaller and without 
a trend favoring one vendor or the other. Formulations 
containing Avicel 102, average powder flow of 16.1 g/s, 
exhibit a something slower powder flow, compared to Al-
facel 102, average powder flow of 17.4 g/s, while Avicel 
101 formulations (average powder flow of 12.0 g/s) show 
a faster powder flow than those formulations with Alfacel 
101 (average powder flow of 6.4 g/s).
The use of different disintegrants had no effect 
on the powder flow. Formulations containing Carmacel 
showed an average powder flow of 13.0 g/s (average of 
the four formulations: 13.7, 13.7, 6.4 and 18.2 g/s) while 
those containing Croscarmellose showed an average 
powder flow of 12.9 (average of the four formulations: 
10.3, 18.5, 6.4 and 16.6 g/s). The excipients dilution in the 
metronidazole formulations mask the better flowability of 
Croscarmellose (2.3 g/s) over that of Carmacel (1.1 g/s), 
determined with the pure excipients and a funnel with an 
opening of 15 mm.
The results of powder flow of metronidazole formula-
tions containing celluloses of the type 101 (Avicel – 12 g/s, 
Alfacel – 6.4 g/s) were consistent with surrogate functionali-
ty tests performed previously using a funnel with an opening 
of 15 mm, showing a faster powder flow for pure Avicel 
PH 101 (2 g/s), compared to that of pure Alfacel type 101 
(0.7 g/s). However, this is not the case for type 102 cellulo-
ses which exhibit similar powder flow in metronidazole for-
mulations (16.1 – 17.4 g/s) while the surrogate functionality 
tests, done earlier using a funnel with an opening of 15 mm, 
clearly show better flow for Avicel 102 (5 g/s) compared to 
Alfacel 102 (0.7 g/s). It is worth mentioning that despite the 
greater particle size of Alfacel type 102, the powder flow 
determined with an opening of 15 mm was similar to that 
of Alfacel type 101. In the same way, it is notable that the 
drug influences the behavior of the different formulations 
but this was beyond the scope of this study and so its effect 
was considered constant.
The initial greater flowability of the innovative 
Croscarmellose, Avicel PH 101 and Avicel PH 102 over 
the generic Carmacel, Alfacel 101 and Alfacel 102, was 
only confirmed in metronidazole formulations for Avicel 
PH 101. The greater flowability of Avicel 102 and Cros-
carmellose over that of Alfacel 102 and Carmacel vanished 
after dilution in metronidazole formulations.
Compactibility
The compactibility, defined as the ability of mate-
rials to form agglomerates after compression, was descri-
bed with equation 1 (Castillo, Villafuerte, 1995a; Castillo, 
Villafuerte, 1995b).
 (1)
FIGURE 1 - Comparative powder flow, through a glass funnel 
with an opening of 20 mm, of formulations containing different 
type and vendor microcrystalline cellulose as diluent and 
Croscarmellose and Carmacel as disintegrant.
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Where: D denotes the tablet’s hardness, Dmax the 
maximal tablet hardness obtained, Pc the compaction 
pressure, n the slope of the curve, and I the intercept of 
the curve.
The compactibility curves obtained depict the rela-
tionship between the hardness or crushing strength of the 
tablets and the compaction pressure used to obtain them. 
Figure 2 shows the experimental data and the calculated 
compactibility curves of formulations designed as F 1, 
F 4, F 5 and F 6, obtained by regression of experimental 
data. These formulations contain Alfacel and Avicel types 
101 and 102 as a diluent and Carmacel as disintegrant. 
The lineal regression was obtained from the data adjusted 
according to equation 1. As can be seen, the data is des-
cribed properly with the applied model. Table III summa-
rizes the regression parameters obtained for all different 
formulations.
Figure 3 shows the calculated tablet crushing strength 
(compaction pressure of 23.9 MPa) for all different formula-
tions. Results clearly show greater compactibility of formu-
lations containing microcrystalline cellulose type 101 (ave-
rage tablet crushing strength of 166 kPa) over those contai-
ning type 102 (average tablet crushing strength of 144 kPa), 
mirroring previous observations (Ahjel, Lupuliasa, 2008). 
These data confirm the higher compactibility of microcrys-
talline cellulose type 101 (average Dmax = 843 kPa) over 
that of the type 102 (average Dmax = 821 kPa) observed 
with surrogate tests (Díaz, Villafuerte, 2010).
A less significant difference in compactibility can be 
observed between the sodium cross-linked carboxymethyl 
celluloses from different vendors, innovator and generic. 
Formulations containing Croscarmellose displayed an 
average crushing strength of 159 kPa while formulations 
containing Carmacel showed an average of 151 kPa. This 
confirms the higher compactibility of Croscarmellose over 
that of Carmacel, determined with the pure excipients, 
although in metronidazole formulations, a much smaller 
difference was seen compared to pure excipients.
Contrasting the compactibilities of microcrystalline 
celluloses from different vendors, reveals that formula-
tions containing Alfacel display greater compactibility or 
crushing strength (169 kPa) when compacted at 23.9 MPa, 
than formulations containing Avicel (141 kPa). These 
results are in contrast with those obtained for pure ex-
FIGURE 2 - Compactibility curves of metronidazole formulations 
containing stearic acid, Carmacel and different diluents. Tablets 
weighed 500 mg and had a diameter of 12.8 mm.
TABLE III - Regression parameters of compactibility curves (Eq. 1) of metronidazole tablets obtained with formulations including 
different types and vendors of microcrystalline cellulose and cross-linked carboxymethylcellulose
Formulation Tablet crushing strength 
Pc=41.7 MPa
(kPa)
 Slope  Intercept r2
F 1 - Avicel PH 101- Carmacel 196 1.312 -12.831 0.960
F 2 - Avicel PH 101- Croscarmellose 184 1.078 -10.499 0.776
F 3 - Alfacel PH 101- Croscarmellose 201 1.331 -12.748 0.915
F 4 - Alfacel PH 101-Carmacel 207 1.491 14.407 0.972
F 5 - Avicel PH 102-Carmacel 146 1.033 -10.171 0.978
F 6 - Avicel PH 102- Croscarmellose 154 1.251 -11.943 0.815
F 7 - Alfacel PH 102-Carmacel 177 1.403 -13.571 0.981
F 8 - Alfacel PH 102-Croscarmellose 193 1.588 -15.159 0.846
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cipients, where Avicel showed a greater compactibility.
In a previous study, the innovative Avicel and 
Croscarmellose showed superior compactibility over the 
generic celluloses Alfacel and Carmacel, assessed with the 
pure excipients. Avicel PH 101 and 102 showed an average 
26 % greater compactibility than the average for both types 
of Alfacel, while the compactibility of Croscarmellose 
was greater than that of Carmacel by about 50% (Díaz, 
Villafuerte, 2010).
It seems that Croscarmellose contributes to a gre-
ater extent than Carmacel to the attained tablet crushing 
strength in metronidazole formulations containing these 
disintegrants, although the difference in compactibility 
is currently only 5% versus the initial 50%. On the other 
hand, the observed greater compactibility of Avicel over 
that of Alfacel of about 26% assessed with the pure exci-
pients, vanished in metronidazole formulations. Metro-
nidazole formulations containing Alfacel display greater 
average compactibility (169 kPa) than those formulations 
containing Avicel (141 kPa). The initial compactibility 
advantage of Avicel (about +26%) became a disadvantage 
(about -20%) in metronidazole formulations.
Although the superior compactibility of Croscar-
mellose over that of Carmacel assessed with pure exci-
pients can be confirmed in metronidazole formulations, 
the difference in compactibility of formulations containing 
these disintegrants is smaller than that initially estimated 
with pure excipients. The initially greater average com-
pactibility of Avicel (26%) over that of Alfacel could not 
be confirmed in metronidazole formulations. Formulations 
containing both types of Alfacel displayed greater com-
pactibility than those containing Avicel.
Ejection pressure of the tablets
The force necessary to eject a tablet involves the dis-
tinctive peak force required to initiate ejection by breaking 
the diewall tablet adhesion. The second stage involves the 
force required to push the tablet up the die wall, and the 
last force is required for ejection of a tablet from the die 
(Patel et al., 2007b).
Figure 4 shows, as an example, curves of ejection 
pressure against compaction pressure of metronidazole 
tablets containing Croscarmellose as disintegrant, and 
Alfacel 101 and 102 as diluent. 
Figure 5 shows the comparative ejection pressure 
of all the different formulations at a compaction pressure 
of 23.9 MPa, calculated after regression of curves similar 
to that of Figure 4. These show that the ejection pressure 
FIGURE 3 - Comparative calculated tablet crushing strength 
attained at a compaction pressure of 23.9 MPa in formulations 
containing different types of microcrystalline cellulose as diluent, 
and two different types of cross-linked carboxymethylcellulose 
as disintegrant.
FIGURE 4 - Curves of ejection pressure for formulations 
containing different diluents, Alfacel type 101 (F3) and 102 
(F8), and Croscarmellose as disintegrant.
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profiles of formulations containing different disintegrants 
show no significant differences. The ejection pressure 
profiles depicted in Figure 4 show the extreme differences 
between the formulations, and both of them are sufficiently 
small to enable fluid production process. These results 
evidence the low ejection pressures that are characteristic 
of materials derived from cellulose while no relevant di-
fference was observed between formulations containing 
different disintegrants and different diluents. The good 
lubricant properties of microcrystalline cellulose mask any 
possible differences due to dissimilar vendors.
DISSOLUTION OF METRONIDAZOLE
The dissolution of metronidazole fast-release for-
mulations was too fast to allow the observation of any 
differences among the formulations. Tablets compacted at 
6 MPa dissolve almost 100% of the drug after 5 minutes. 
The same occurred with tablets compacted at 47 MPa, 
dissolving almost the total quantity of the drug after 5 
min. This type of tablet, with water soluble drugs, display 
the same good dissolution results regardless of the type 
or vendor of microcrystalline cellulose (101 or 102) and 
sodium cross-linked carboxymethyl cellulose used.
In order to disclose any differences as disintegrant 
or dissolution facilitating agents of sodium cross-linked 
carboxymethyl celluloses from different vendor, the re-
lease rate of metronidazole formulations was slowed down 
using Gelucire 39/01. Table 2 shows the different metroni-
dazole formulations containing Gelucire, as a dissolution 
restricting agent, and Croscarmellose and Carmacel as 
disintegrants or dissolution facilitating agents. The dis-
solution behaviour was the only determined characteristic 
of these formulations and was determined in granules as 
well as tablets obtained with these granules, compacted 
at 47 MPa.
Figure 6 shows the dissolution profiles of metronida-
zole (50 parts) floating granules containing Gelucire 39/01 
(40 parts) and different proportions of Croscarmellose and 
Carmacel (5, 10 and 15 parts). The dissolution profiles, 
although different for different disintegrants, do not show 
a tendency indicating better functionality of any one of 
the disintegrants. Using formulations containing 5 parts 
of the disintegrants, Carmacel formulations exhibited a 
higher dissolution rate over Croscarmellose formulations. 
However, upon using 10 parts of the disintegrant instead 
of 5 parts, the opposite occurred. The use of 15 parts of 
the disintegrant showed overlapping dissolution profiles 
for formulations containing both disintegrants.
FIGURE 5 - Comparative calculated ejection pressure (Pc=23.9 
MPa) of formulations containing different type and vendor 
microcrystalline cellulose as diluent and Croscarmellose and 
Carmacel as disintegrant.
FIGURE 6 - Dissolution of metronidazole (50 parts) granules 
containing Gelucire 39/01 (40 parts) and different proportions 
of Croscarmellose (Crosca) or Carmacel P (CC) (Carma) (5, 10 
and 15 parts).
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The better tablet disintegrating properties showed 
by pure Carmacel over pure Croscarmellose disappears 
in metronidazole floating granules formulations. Metro-
nidazole floating granules containing Carmacel did not 
dissolve faster than granules containing Croscarmellose, 
as could be expected because of the better disintegrating 
properties showed by Carmacel in tablets of the pure 
excipients.
Increases in disintegrant proportion were accompa-
nied by increases in drug dissolution, with a tendency to 
attain a limit not corresponding with the total drug con-
tent but apparently corresponding with the ability of the 
lipidic Gelucire to conceal the drug from the dissolution 
medium. An explanation for these results is that increasing 
proportions of the disintegrant dilutes or decreases the 
possibility to cover the drug with Gelucire, allowing a 
greater quantity of metronidazole to interact directly with 
the dissolution medium. However, it is also possible that 
increasing proportions of the swelling disintegrant open up 
the Gelucire structure to a greater extent, forming channels 
that facilitate drug dissolution. The channelling increases 
with greater proportions of Carmacel and Croscarmellose. 
This means that Croscarmellose and Carmacel behave in 
the same manner and have the same power to facilitate the 
dissolution from the floating granules.
Whatever the case may be, a part of the drug that 
remains completely covered with the lipophilic Gelucire 
could not be dissolved. Increasing proportions of the disin-
tegrants make a greater proportion of the drug accessible to 
the dissolution medium. In this way, greater proportions of 
the disintegrants allow a greater plateau of drug dissolution 
to be attained, independently of the disintegrant used.
Figure 7 shows the dissolution profiles of metroni-
dazole tablets obtained with the floating granules. In this 
case, Croscarmellose displays a greater functionality as 
an agent favouring drug dissolution, functionality that 
decreases at low disintegrant proportions. Croscarmellose 
formulations exhibit greater release rates at proportions 
of 10 and 15 parts of the disintegrant. However, at low 
disintegrant proportions (5 parts) metronidazole tablets 
containing Croscarmellose or Carmacel display over-
lapping drug dissolution profiles. Unlike the granules, 
the tablets do not float. The non-floating tablets release 
the drug in a more gradual manner. The dissolved drug 
increased continuously with time throughout the 6 hours 
of the dissolution test.
Generally, the use of Gelucire slowed down the rele-
ase rate of metronidazole. From dissolution rates allowing 
almost total drug dissolution in less than 5 minutes, Gelu-
cire granules allow a metronidazole dissolution ranging 
FIGURE 7 - Metronidazole (50 parts) dissolution from tablets 
containing Gelucire 39/01 (40 parts) and different proportions 
(5, 10 and 15 parts) of Croscarmellose (Crosca) or Carmacel P 
(CC) (Carma), obtained at Pc=47 MPa.
FIGURE 8 - Effect of disintegrant proportion (5, 10 and 15 parts) 
on average metronidazole (50 parts) dissolution after 4 hours, 
from granules and tablets containing Gelucire 39/01 (40 parts) 
and Croscarmellose or Carmacel P (CC).
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from an average of 38% to almost total drug dissolution 
(98%) after 4 hours, while the tablets allowed the drug 
dissolution in a range from 7.5% to 95% after the same 
4-hr period. In both cases the tendency shows increasing 
drug dissolution at higher disintegrant proportions. This 
behavior can be seen in Figure 8. Although the drug dis-
solution was sufficiently slowed down with the tablets, it 
is necessary to review their deficit in floatability.
CONCLUSION
The conclusion of this work has to be addressed in 
two parts, first a conclusion about the predictability of 
an excipient behavior in a given formulation through the 
knowledge of surrogate functionality test, and secondly a 
conclusion about the functionality of excipients from diffe-
rent sources or vendors, innovative and generic excipients.
Although the surrogate tests do not precisely reflect 
the excipients’ behavior in a formulation they remain good 
indicators of their potential functioning, particularly when 
the excipients are used in higher proportions. It should to 
be taken in account that dilution of the excipients decre-
ases their influence on the formulation performance and 
this means the predictability of their functioning becomes 
more uncertain.
The differences in performance of the excipients 
obtained from different vendors revealed that the generic 
sodium cross-linked carboxymethyl cellulose traded as 
Carmacel has the advantage over the innovative Cros-
carmellose of better disintegrating properties, while 
Croscarmellose exhibited greater compactibility than 
Carmacel, assessed with pure excipients. Nevertheless, 
these advantages could not be confirmed in fast-releasing 
metronidazole formulations, neither in the floating granu-
les nor in the prolonged-release tablets. The higher com-
pactibility of Avicel over Alfacel could not be confirmed 
with metronidazole fast-release formulations. None of the 
excipients displayed any advantage over the other in the 
compactibility of metronidazole formulations. However, 
greater compactibility of microcrystalline cellulose type 
101 over that of type 102 was clear. On the other hand, 
both trade names of microcrystalline cellulose, Alfacel and 
Avicel, showed similar powder flow properties in metroni-
dazole formulations. However, type 102 microcrystalline 
celluloses showed a higher powder flow compared to type 
101 microcrystalline celluloses. The excipients dilution 
produces an equalization of their influence on the formu-
lation performance.
As the excipients are increasingly diluted, the original 
differences obtained with the pure excipients or surrogate 
functionality tests have a tendency to disappear. Compari-
son of the innovative celluloses, Avicel and Croscarmellose, 
against the generic celluloses, Alfacel and Carmacel, show 
no definitive better performance of one over the other. The 
innovative celluloses showed some advantages and some 
disadvantages over the generics. In any event, the differen-
ces in performance tended to disappear as the excipients 
were diluted in the formulation, equalizing the excipients’ 
influence on the formulation performance.
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